ARCHIVES

Second-Generation CML Drugs Show Promise For Frontline

This article is from The Cancer Letter archive.

Vol. 31 No. 12 | December 26, 2008

Download PDF Visit The Full Archive

Related Articles

Klausner Reaffirms NCI’s “No. 1 Priority” Is Funding investigator-Initiated Research

September 13, 1996

NCI Encourages IP Chemo For Stage III Ovarian Cancer

January 27, 2006

ASCO Highlights Six Studies From Meeting To Showcase Advances In Cancer Care

May 30, 2008

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

September 28, 2012

RFA On Hepatitis B Virus, Liver Cancer

April 15, 1983

House Committee Asks Varmus About Impact of Clinical Center construction On NIH Programs

April 26, 1996